Related Experiment Video
Updated: Apr 30, 2026
Modeling Brain Metastasis by Internal Carotid Artery Injection of Cancer Cells
Published on: August 2, 2022
Systemic treatment of HER2-positive metastatic breast cancer: a systematic review
Nicholas Wilcken1, Nicholas Zdenkowski, Michelle White
1Westmead Hospital, New South Wales, Australia.
Aim:
We aimed to systematically review and summarize data from the available clinical trials that examined the treatment of HER2-positive metastatic breast cancer.
Methods:
We reviewed phase 2 and 3 studies in which an anti-HER2 agent was used in one or both arms of the study. While formal meta-analysis was not possible for such a heterogeneous group of trials, resulting forest plots outline some generalizable findings.
Results:
There is strong evidence that the addition of an anti-HER2 agent to standard chemo- or endocrine therapy improves clinically relevant measurable outcomes. There is also consistent evidence that initial treatment with trastuzumab alone (and subsequent use of a cytotoxic) is inferior to the initial combination of trastuzumab plus chemotherapy, and that either T-DM1 or dual anti-HER2 agents are superior to single anti-HER2 agent regimens. There is no strong evidence that the use of more than one cytotoxic agent together with an anti-HER2 agent confers any benefit over a single cytotoxic, anti-HER2 combination.
Conclusion:
This review provides a strong evidence base for current clinical practice with a discussion of treatment in the Australian setting.
Insights
Adding anti-HER2 agents to standard therapy significantly improves outcomes for HER2-positive metastatic breast cancer. Combination therapies, like trastuzumab plus chemotherapy or T-DM1, are superior to single-agent treatments.
Area of Science:
- Oncology
- Medical Research
- Pharmacology
Background:
- HER2-positive metastatic breast cancer remains a significant clinical challenge.
- Effective treatment strategies are crucial for improving patient outcomes.
- Anti-HER2 agents have revolutionized the management of this disease.
Purpose of the Study:
- To systematically review and synthesize data from clinical trials on HER2-positive metastatic breast cancer treatment.
- To summarize the efficacy of anti-HER2 agents in various treatment combinations.
- To provide evidence-based recommendations for clinical practice.
Main Methods:
- Systematic review of Phase 2 and 3 clinical trials.
- Inclusion of studies utilizing anti-HER2 agents in treatment arms.
- Qualitative synthesis of findings due to trial heterogeneity; forest plots used for generalizable insights.
Main Results:
- Addition of anti-HER2 agents to chemotherapy or endocrine therapy significantly improves measurable outcomes.
- Initial combination of trastuzumab plus chemotherapy is superior to trastuzumab alone.
- T-DM1 or dual anti-HER2 agents demonstrate superiority over single anti-HER2 agent regimens; no added benefit from multiple cytotoxic agents.
Conclusions:
- Strong evidence supports the use of anti-HER2 agents in combination therapies for HER2-positive metastatic breast cancer.
- This review reinforces current clinical guidelines and informs treatment decisions.
- Discussion includes specific considerations for the Australian healthcare setting.
More Related Videos
08:57Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice
Published on: October 5, 2017
14:20Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
Published on: June 13, 2014
Related Concept Videos
02:56Treatment Resistant Cancers
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:56Treatment Resistent Cancers
01:27Tumor Immunotherapy
02:30Metastasis